FDA Approves Weekly Lecanemab Dosage for Alzheimer's Treatment

The FDA's approval of a weekly dosage for lecanemab can be considered a positive catalyst for BIIB. This news may enhance the drug's market potential by offering a more flexible and patient-friendly option for Alzheimer's treatment. Technically, although the stock is trading below its 20- and 50-day moving averages, the RSI in neutral territory and the MACD approaching its signal line could signal a short-term recovery. However, the price remaining below SMA20 and SMA50 suggests that any upside may be limited.

The FDA's approval of a weekly dosage of Lecanemab for Alzheimer's treatment could serve as a positive catalyst for LLY. However, the stock fell 3.16% in the last close, with its RSI approaching oversold territory at 33.6. Although the MACD remains below the signal line and in negative territory, this news could trigger a short-term recovery move. While trading below the SMA20 and SMA50 presents a technically weak outlook, the positive news flow and oversold conditions create potential for a short-term upward movement.

The FDA's approval of a weekly lecanemab dosage could be considered a positive catalyst for AstraZeneca (AZN). However, the stock closed down 2.4% in the last session, with an RSI of 40, indicating weak short-term momentum. Although the MACD remains in negative territory, it has crossed above the signal line, which may signal a potential upward move. While the SMA20 being below the SMA50 presents a technically weak outlook, a short-term recovery could be expected on the back of the news. Still, the market's reaction to the news may be limited, so the upside expectation is expressed with moderate confidence.